Neuroblastoma

Causes
Symptoms
Diagnosis
Treatment

Neuroblastoma is a cancerous tumor that forms in nerve tissue. Specifically, it develops from immature nerve cells called neuroblasts, which are found in various parts of the body, primarily in the adrenal glands (located on top of the kidneys), abdomen, chest, neck, or pelvis. These tumors can vary in size, ranging from small and localized to large and spreading to other parts of the body.

Types

For different types of neuroblastoma

Localized Neuroblastoma: Localized neuroblastoma refers to a type of neuroblastoma that is confined to its site of origin and has not spread to other parts of the body. This type of neuroblastoma is commonly found in children younger than 1 year old. It is usually associated with a favorable prognosis, as it tends to respond well to treatment.
Regional Neuroblastoma: Regional neuroblastoma refers to a type of neuroblastoma that has spread to nearby lymph nodes, but not to distant parts of the body. The lymph nodes are small bean-shaped structures that help fight infections. In regional neuroblastoma, the cancer cells have reached these nodes, indicating a slightly more advanced stage of the disease compared to localized neuroblastoma. However, with appropriate treatment, the prognosis can still be favorable.
Metastatic Neuroblastoma: Metastatic neuroblastoma is the most aggressive form of the disease. It occurs when the cancer cells have spread to distant parts of the body beyond the original site. Common sites of metastasis include the bones, bone marrow, liver, and skin. Metastatic neuroblastoma often presents with more severe symptoms and requires more intensive treatment. The prognosis for metastatic neuroblastoma can vary depending on factors such as age, stage of disease, and genetic markers.
Stage 4S Neuroblastoma: Stage 4S neuroblastoma, also known as special neuroblastoma, is a unique subtype that typically affects infants younger than 1 year old. It is characterized by a specific pattern of metastasis, primarily involving the liver, skin, and bone marrow. Despite the widespread dissemination of the disease, stage 4S neuroblastoma has a relatively good prognosis, and spontaneous regression is observed in some cases without aggressive treatment.
MYCN-Amplified Neuroblastoma: MYCN-amplified neuroblastoma refers to a subtype of neuroblastoma in which the MYCN gene, responsible for cell growth and division, is abnormally amplified. This genetic alteration is associated with more aggressive tumor behavior and a poorer prognosis. Children with MYCN-amplified neuroblastoma often require more intensive treatments, including chemotherapy, surgery, radiation therapy, and stem cell transplantation.
Non-MYCN-Amplified Neuroblastoma: Non-MYCN-amplified neuroblastoma is a subtype of neuroblastoma in which the MYCN gene is not amplified. This subtype is generally associated with a better prognosis compared to MYCN-amplified neuroblastoma. However, treatment decisions are still based on other factors such as age, stage of disease, and the presence of other genetic markers.

Causes

Understanding the causes and risk factors associated with neuroblastoma can help raise awareness, facilitate early detection, and promote effective prevention strategies

Genetic Predisposition: Some children inherit gene mutations from their parents that increase the risk of developing neuroblastoma. Genetic conditions such as neurofibromatosis and Beckwith-Wiedemann syndrome are associated with a higher incidence of neuroblastoma.
Chromosomal Abnormalities: Certain chromosomal abnormalities, such as gain or loss of genetic material in chromosome 1p, 11q, or 17q, have been linked to an increased susceptibility to neuroblastoma.
Age: Neuroblastoma primarily affects children under the age of five, with the highest incidence occurring in infants. It is rare in older children and adults.
Race and Ethnicity: Studies have shown that neuroblastoma occurs more frequently in Caucasian children compared to children of African, Asian, or Hispanic descent. However, the reasons for this disparity remain unclear.
Familial History: Having a sibling diagnosed with neuroblastoma increases the risk for other siblings. Additionally, a family history of other cancers, such as breast cancer, may elevate the likelihood of developing neuroblastoma.
Maternal Factors: Certain maternal factors during pregnancy, such as exposure to environmental toxins or the mother’s age, may influence the risk of neuroblastoma in the child. However, these associations require further research.
Parental Occupational Exposure: Exposure to certain chemicals or substances in the workplace, such as pesticides or solvents, may increase the risk of neuroblastoma in children.
Maternal Smoking: Maternal smoking during pregnancy has been linked to an increased risk of neuroblastoma in children. Quitting smoking or avoiding exposure to secondhand smoke is crucial for reducing this risk.
Maternal Drug Use: The use of certain drugs during pregnancy, including certain fertility treatments, has been associated with a higher incidence of neuroblastoma. Consultation with healthcare professionals is important to weigh the risks and benefits.
Birth Weight: Low birth weight has been suggested as a potential risk factor for neuroblastoma. However, more research is needed to establish a conclusive relationship.
Prenatal X-ray Exposure: Exposure to X-rays during pregnancy, particularly in high doses or multiple instances, may contribute to an increased risk of neuroblastoma. Medical professionals should carefully evaluate the necessity of any prenatal radiation exposure.
Ionizing Radiation: Exposure to high levels of ionizing radiation, such as from nuclear accidents or radiation therapy for other conditions, may elevate the risk of developing neuroblastoma.
Diethylstilbestrol (DES) Exposure: In rare cases, neuroblastoma has been linked to maternal exposure to DES, a synthetic hormone used between the 1940s and 1970s to prevent miscarriage. This exposure is now uncommon.
Viral Infections: Certain viral infections, such as human herpesvirus-6 and human T-cell leukemia virus type 1 (HTLV-1), have been investigated as potential risk factors for neuroblastoma. However, more research is required to establish a definitive link.
Neuroblastoma History: Children who have previously had neuroblastoma are at an increased risk of developing a secondary neuroblastoma or other cancers later in life. Regular monitoring and follow-up care are essential.
Environmental Factors: Exposure to certain environmental toxins, such as pesticides, heavy metals, and industrial pollutants, has been suggested as a potential risk factor for neuroblastoma. Minimizing exposure to these substances is important.
Dietary Factors: Although no specific dietary factors have been definitively linked to neuroblastoma, maintaining a healthy and balanced diet may contribute to overall well-being and potentially reduce cancer risk.
Hormonal Imbalances: Some studies suggest that hormonal imbalances, particularly in the levels of certain hormones like norepinephrine and dopamine, may play a role in neuroblastoma development. Further research is necessary to establish a concrete link.
Immune System Abnormalities: Certain immune system abnormalities or dysfunctions may increase the risk of neuroblastoma. Understanding and addressing these underlying conditions may be important for prevention.
Neuroblastoma-associated Genes: Several genes, including ALK, PHOX2B, and MYCN, have been identified as potential contributors to neuroblastoma development. Mutations or alterations in these genes may increase the risk.
Hormonal Factors: Neuroblastoma is more common in boys than girls, suggesting that certain hormonal factors may play a role in its occurrence. However, the exact mechanisms remain unclear.
Exposure to Chemicals and Toxins: Exposure to certain chemicals and toxins, such as benzene and certain solvents, has been associated with an increased risk of neuroblastoma. Reducing exposure to these substances is essential.
Hormonal Replacement Therapy: Maternal use of hormonal replacement therapy, especially during pregnancy, may be linked to a higher risk of neuroblastoma in children. Consultation with healthcare professionals is crucial.
Immune System Suppression: Children with compromised or suppressed immune systems, such as those undergoing organ transplantation or receiving immunosuppressive therapy, may have an elevated risk of neuroblastoma.
Alcohol Consumption: Maternal alcohol consumption during pregnancy has been suggested as a possible risk factor for neuroblastoma. Avoiding alcohol during pregnancy is advised to minimize risks.
Obesity: Some studies have indicated a potential association between childhood obesity and an increased risk of neuroblastoma. Promoting a healthy weight through balanced nutrition and physical activity is beneficial.
Hormonal Birth Control: The use of hormonal birth control methods, such as oral contraceptives, has been examined as a potential risk factor for neuroblastoma. However, more research is needed to establish a conclusive link.
Personal History of Certain Birth Defects: Children with certain birth defects, such as congenital heart defects or abnormalities in the structure of the abdominal wall, may have a higher risk of developing neuroblastoma.
Inherited Genetic Syndromes: Certain genetic syndromes, such as Down syndrome (trisomy 21) and Hirschsprung disease, are associated with an increased risk of neuroblastoma. Regular screening and genetic counseling are crucial.
Socioeconomic Factors: Although the exact relationship remains complex, studies have suggested that socioeconomic factors, such as lower income and limited access to healthcare, may influence the risk of neuroblastoma.

Symptoms

Common symptoms of neuroblastoma, providing detailed explanations to help you recognize the signs and seek appropriate medical attention for your child.

Abdominal pain: Children with neuroblastoma may experience abdominal pain, which can range from mild discomfort to severe pain. The pain may be persistent or intermittent, and it may worsen over time.
Swelling or lump in the abdomen: A noticeable lump or swelling in the child’s abdomen, usually on one side, may indicate neuroblastoma. This lump is caused by the tumor growing and pressing against surrounding organs.
Anemia: Anemia refers to a low red blood cell count. Children with neuroblastoma may develop anemia, leading to fatigue, pale skin, and weakness. If your child appears unusually tired or weak, consult a healthcare professional.
Weight loss: Unexplained weight loss in children is concerning and should be evaluated further. Neuroblastoma can affect the child’s appetite, leading to unintentional weight loss.
Loss of appetite: Neuroblastoma can cause a loss of appetite in affected children. This may result in decreased food intake and subsequent weight loss.
Fatigue: Persistent fatigue or tiredness is a symptom that should not be ignored. Neuroblastoma can disrupt normal body functions, leading to increased fatigue and decreased energy levels.
Bone pain: Children with neuroblastoma may experience bone pain, especially in the legs, arms, or lower back. If your child complains of ongoing or worsening bone pain, consult a healthcare professional.
Bruising or bleeding: Unexplained bruising or bleeding tendencies, such as nosebleeds or easy bruising, can be an indication of neuroblastoma. Seek medical attention if you notice these symptoms.
Fever: Frequent or persistent fever, often accompanied by other symptoms, may be a sign of neuroblastoma. Consult a healthcare professional if your child experiences unexplained fever.
Swelling in the legs or face: Neuroblastoma can cause swelling in various parts of the body, such as the legs or face. This swelling may be due to tumor growth or the cancer affecting the lymphatic system.
Changes in eye movements: Neuroblastoma tumors near the eyes can affect eye movement and coordination. If you notice changes in your child’s eye movements, such as abnormal jerking or drifting, consult a healthcare professional.
Proptosis: Proptosis refers to the abnormal protrusion or bulging of one or both eyes. This can be a symptom of neuroblastoma, indicating the presence of a tumor behind the eye.
Persistent cough: Neuroblastoma can sometimes spread to the chest, leading to a persistent cough that doesn’t go away. If your child has a chronic cough, it is advisable to have it evaluated by a healthcare professional.
Difficulty breathing: Children with neuroblastoma may experience difficulty breathing due to tumor growth or the tumor affecting nearby organs. Prompt medical attention is necessary if your child has breathing difficulties.
Blueberry muffin spots: These are small, dark blue or purple spots that may appear on the skin. Blueberry muffin spots can indicate the presence of neuroblastoma, and their appearance should be evaluated by a healthcare professional.
Diarrhea: Persistent diarrhea, especially when accompanied by other symptoms, should be investigated further. Neuroblastoma can affect the digestive system, leading to diarrhea in affected children.
High blood pressure: Neuroblastoma can cause elevated blood pressure in children. If your child’s blood pressure is consistently high, it is essential to consult a healthcare professional.
Horner syndrome: Horner syndrome refers to a combination of symptoms caused by damage to a group of nerves. Neuroblastoma tumors can disrupt these nerves, resulting in symptoms such as drooping eyelids and decreased sweating on one side of the face.
Neurological changes: Neuroblastoma can affect the nervous system, leading to various neurological changes. These may include weakness, numbness, or coordination difficulties.
General malaise: Children with neuroblastoma may experience a general sense of discomfort or unease, often described as malaise. If your child seems consistently unwell without an obvious cause, seek medical attention.

Diagnosis

To aid in the early detection of neuroblastoma, medical professionals employ a range of diagnostic tests.

Physical Examination: During a physical examination, a healthcare provider will assess the child’s overall health, looking for any signs or symptoms that may indicate the presence of neuroblastoma.
Medical History Evaluation: Reviewing the child’s medical history is crucial in understanding any previous illnesses or conditions that might be relevant to the development of neuroblastoma.
Urine Tests: Urine tests can detect elevated levels of certain chemicals and substances produced by neuroblastoma cells, such as vanillylmandelic acid (VMA) and homovanillic acid (HVA).
Blood Tests: Blood tests can help evaluate the levels of specific markers, such as catecholamines, which are often elevated in neuroblastoma cases.
Imaging Studies: Various imaging techniques can be employed to visualize the tumor and determine its size, location, and potential spread. These include:
- Ultrasound: Uses sound waves to create images of the body’s internal structures.
- X-rays: Provide detailed pictures of the bones and surrounding tissues.
- Computed Tomography (CT) Scan: Combines X-ray images taken from different angles to create cross-sectional views of the body.
- Magnetic Resonance Imaging (MRI): Uses powerful magnets and radio waves to generate detailed images of the body’s soft tissues.
- Metaiodobenzylguanidine (MIBG) Scan: Involves the injection of a radioactive substance that selectively accumulates in neuroblastoma cells, making them visible on a special camera.
Biopsy: A biopsy involves the extraction of a small sample of tissue from the tumor, which is then examined under a microscope to confirm the presence of neuroblastoma.
Bone Marrow Aspiration and Biopsy: This procedure helps determine whether neuroblastoma has spread to the bone marrow by collecting samples from the bone marrow for analysis.
Genetic Testing: Genetic tests can identify specific gene mutations or chromosomal abnormalities associated with neuroblastoma, providing important information for treatment planning.
Immunohistochemistry: Immunohistochemistry is a specialized test that uses antibodies to detect specific proteins on the surface of neuroblastoma cells, aiding in diagnosis and classification.
Fluorescence In Situ Hybridization (FISH): FISH is a genetic test that examines chromosomes and genes to identify any abnormalities associated with neuroblastoma.
MYCN Amplification Testing: MYCN amplification is a genetic alteration commonly found in aggressive neuroblastoma cases. Testing for MYCN amplification helps determine the severity of the disease and guide treatment decisions.
Oncogene Panel Testing: This genetic test analyzes multiple genes associated with cancer development, helping identify additional mutations that may influence the course of neuroblastoma.
Flow Cytometry: Flow cytometry is a technique used to assess the characteristics and behavior of cells, aiding in the diagnosis and classification of neuroblastoma.
Immunocytology: Immunocytology is a test that examines the presence of specific proteins or antigens on neuroblastoma cells, supporting the diagnosis and monitoring of the disease.
Bone Scan: A bone scan uses a radioactive substance to detect whether neuroblastoma has spread to the bones, providing valuable information for staging the disease.
Metaiodobenzylguanidine (MIBG) Therapy: MIBG therapy involves the use of a radioactive substance that selectively targets and destroys neuroblastoma cells, improving the chances of successful treatment.
Positron Emission Tomography (PET) Scan: PET scans utilize a radioactive substance to create detailed images that help determine the extent and spread of neuroblastoma throughout the body.
Magnetic Resonance Spectroscopy (MRS): MRS is a specialized MRI technique that measures the levels of certain chemicals within the tumor, aiding in the diagnosis and monitoring of neuroblastoma.
Sentinel Lymph Node Biopsy: This procedure involves removing the sentinel lymph node, the first lymph node to which the cancer is most likely to spread, to determine if neuroblastoma has metastasized.
Bone Marrow Transplant Evaluation: In cases where neuroblastoma has spread to the bone marrow, a bone marrow transplant may be considered. Evaluation helps assess the suitability of the procedure.
Surgical Exploration: Surgical exploration is performed to determine the extent of the tumor and its involvement with surrounding structures, aiding in treatment planning.
Nerve Conduction Studies: Nerve conduction studies assess the functionality of nerves near the tumor site, helping determine the extent of nerve involvement and guiding treatment decisions.
Electroencephalogram (EEG): EEG records the electrical activity of the brain and can be helpful in assessing neurologic complications associated with neuroblastoma.
Lumbar Puncture: Also known as a spinal tap, a lumbar puncture involves collecting cerebrospinal fluid to detect any tumor involvement in the central nervous system.
Chromogranin A Testing: Chromogranin A is a hormone produced by neuroblastoma cells. Elevated levels of this hormone can indicate the presence of the disease and its response to treatment.
Surgical Biopsy: A surgical biopsy involves the removal of a larger tissue sample for detailed analysis, aiding in the accurate diagnosis and determination of tumor characteristics.
Exploratory Laparotomy: An exploratory laparotomy is a surgical procedure used to examine the abdomen and pelvis to determine the extent of tumor spread.
Electrocardiogram (ECG): ECG measures the electrical activity of the heart, assessing any cardiac complications related to neuroblastoma or its treatment.
Pulmonary Function Tests: Pulmonary function tests evaluate lung capacity and function, helping monitor any respiratory complications associated with neuroblastoma.
Consultation with Specialists: Consulting with various specialists, such as pediatric oncologists, radiologists, and pathologists, plays a crucial role in ensuring accurate diagnosis, staging, and treatment planning for neuroblastoma.

Treatment

Effective treatments for neuroblastoma, providing valuable information to enhance its visibility and accessibility

Surgery: Surgery involves removing the tumor and nearby lymph nodes. It is often the initial step to treat localized neuroblastoma.
Chemotherapy: Chemotherapy uses drugs to kill cancer cells throughout the body. It can be administered before surgery to shrink tumors or after surgery to target remaining cancer cells.
Radiation Therapy: Radiation therapy utilizes high-energy X-rays or other radiation sources to destroy cancer cells. It can be used before or after surgery to kill remaining cancer cells.
Stem Cell Transplant: High-dose chemotherapy is followed by a stem cell transplant to replace damaged bone marrow with healthy stem cells, aiding recovery.
Immunotherapy: Immunotherapy enhances the body’s immune system to recognize and destroy cancer cells. Antibodies or immune checkpoint inhibitors are used to stimulate the immune response.
Targeted Therapy: Targeted therapy drugs specifically target cancer cells, interfering with their growth and survival while minimizing damage to healthy cells.
Retinoid Therapy: Retinoids, derived from vitamin A, are used to induce maturation and cell death in neuroblastoma cells.
Radiofrequency Ablation: This technique uses heat generated by high-frequency radio waves to destroy cancer cells.
MIBG Therapy: MIBG is a radioactive substance that selectively attaches to neuroblastoma cells. It emits radiation, destroying cancer cells.
Monoclonal Antibody Therapy: Monoclonal antibodies are designed to bind to specific molecules on cancer cells, flagging them for destruction by the immune system.
Tumor Vaccines: Tumor vaccines stimulate the immune system to recognize and attack cancer cells, helping prevent the spread or recurrence of neuroblastoma.
Proton Therapy: Proton therapy delivers precise radiation doses to tumors, reducing damage to surrounding healthy tissues.
Cryotherapy: Extreme cold temperatures are used to freeze and destroy cancer cells.
Angiogenesis Inhibitors: These drugs target blood vessels that supply nutrients to tumors, inhibiting their growth.
Biologic Response Modifiers: These substances modify the body’s response to cancer cells, aiding in the destruction of tumors.
Gene Therapy: Gene therapy aims to correct genetic abnormalities in neuroblastoma cells, either by replacing faulty genes or introducing new ones.
Arginine Deprivation Therapy: This treatment deprives neuroblastoma cells of arginine, an amino acid essential for their growth.
Antiangiogenic Therapy: Drugs that interfere with the formation of new blood vessels, thus starving the tumor of nutrients, are used in this therapy.
Differentiation Therapy: Differentiation therapy encourages cancer cells to mature into normal cells, limiting their ability to grow and divide.
Photodynamic Therapy: Cancer cells are targeted with a photosensitizing agent, which becomes activated when exposed to specific light wavelengths, killing the cells.
Supportive Care: Supportive care aims to manage symptoms, provide pain relief, and improve the overall quality of life for neuroblastoma patients.
Palliative Care: Palliative care focuses on relieving symptoms, managing pain, and providing emotional support for patients with advanced neuroblastoma.
Clinical Trials: Participating in clinical trials offers access to innovative treatments that may not be widely available, contributing to advancements in neuroblastoma treatment.
Tumor Resection: Surgical removal of the tumor is performed in cases where it is feasible and safe.
Intrathecal Therapy: Chemotherapy drugs are delivered directly into the cerebrospinal fluid to target neuroblastoma cells in the central nervous system.
COG Protocol Therapy: COG (Children’s Oncology Group) protocols are standardized treatment plans that incorporate the latest research and guidelines for managing neuroblastoma.
Support Groups: Joining support groups allows patients and families to connect with others facing similar challenges, providing emotional support and valuable resources.
Psychological Counseling: Psychological counseling helps patients and families cope with the emotional impact of neuroblastoma, offering guidance and support.
Nutritional Support: A well-balanced diet and proper nutritional support are essential for maintaining strength and overall well-being during neuroblastoma treatment.
Follow-up Care: Regular follow-up visits with healthcare professionals are crucial to monitor the patient’s progress, detect any potential recurrence, and address any ongoing concerns.

Medications

Highly effective drugs that are used to combat this aggressive cancer.

Cyclophosphamide: Cyclophosphamide is a chemotherapy drug that targets rapidly dividing cells, including cancer cells. It works by damaging the DNA of cancer cells, preventing their growth and division. Common side effects include hair loss, nausea, and increased risk of infection.
Cisplatin: Cisplatin is another chemotherapy drug that interferes with cancer cell DNA, causing them to die. It is often used in combination with other drugs. Side effects may include kidney damage, hearing loss, and nausea.
Carboplatin: Similar to cisplatin, carboplatin disrupts cancer cell DNA, inhibiting their growth. It is less toxic than cisplatin, with side effects such as bone marrow suppression, nausea, and anemia.
Doxorubicin: Doxorubicin is a chemotherapy drug that blocks the growth of cancer cells by preventing DNA replication. Side effects may include hair loss, nausea, and increased risk of infection.
Vincristine: Vincristine is a vinca alkaloid that interferes with the formation of microtubules, essential for cell division. It can cause nerve damage, constipation, and hair loss.
Topotecan: Topotecan inhibits the activity of an enzyme involved in DNA replication, leading to the death of cancer cells. Common side effects include bone marrow suppression, nausea, and diarrhea.
Irinotecan: Irinotecan interferes with DNA replication by inhibiting a specific enzyme. Side effects may include diarrhea, low blood counts, and fatigue.
Busulfan: Busulfan is a chemotherapy drug that disrupts DNA synthesis in cancer cells, ultimately leading to cell death. It can cause bone marrow suppression, mouth sores, and nausea.
Isotretinoin: Isotretinoin is a retinoid drug that differentiates neuroblastoma cells, making them more susceptible to other therapies. Side effects may include dry skin, increased sun sensitivity, and muscle or joint pain.
MIBG (metaiodobenzylguanidine): MIBG is a radioactive drug that selectively targets and kills neuroblastoma cells. It is administered intravenously and can cause low blood counts and nausea.
Retinoic Acid: Retinoic acid is a vitamin A derivative that promotes cell differentiation and inhibits tumor growth. Side effects may include dry skin, increased sun sensitivity, and liver toxicity.
Dinutuximab: Dinutuximab is an immunotherapy drug that targets a specific protein on neuroblastoma cells, stimulating the immune system to attack the cancer. Common side effects include pain, allergic reactions, and fever.
Bevacizumab: Bevacizumab is a targeted therapy that inhibits the formation of blood vessels that feed tumors. It may lead to hypertension, bleeding, and impaired wound healing.
Rituximab: Rituximab is an immunotherapy drug that targets a protein on certain immune cells, effectively killing cancer cells. Side effects may include infusion reactions, fever, and infections.
131I-MIBG: Similar to MIBG, 131I-MIBG is a radioactive drug used for targeted radiation therapy in neuroblastoma. It can cause low blood counts and nausea.
Temsirolimus: Temsirolimus is a targeted therapy that inhibits a protein involved in cancer cell growth. Side effects may include mouth sores, low blood counts, and high blood glucose.
Everolimus: Everolimus works similarly to temsirolimus, inhibiting the same protein. It can cause mouth sores, low blood counts, and increased risk of infections.
Sorafenib: Sorafenib is a targeted therapy that inhibits several proteins involved in tumor growth. Side effects may include hand-foot syndrome, diarrhea, and high blood pressure.
Sunitinib: Sunitinib is another targeted therapy that blocks proteins responsible for tumor growth. Common side effects include fatigue, diarrhea, and hand-foot syndrome.
Crizotinib: Crizotinib is a targeted therapy that inhibits a specific gene mutation found in some neuroblastoma cases. Side effects may include nausea, diarrhea, and liver toxicity.

Conclusion:

The treatment landscape for neuroblastoma has significantly evolved, with various drug therapies playing a crucial role in fighting this aggressive childhood cancer. These 20 drugs, each with its own mechanism of action, have shown effectiveness in targeting and killing neuroblastoma cells. While they offer hope, it’s important to note that each drug can have potential side effects. As always, it is crucial to consult with healthcare professionals for personalized treatment plans and to closely monitor the patient’s well-being throughout the treatment journey.

References